Drug Metabolism and Drug Interactions
Drug Metabolism and Drug Interactions is the official journal of the European Society of Pharmacogenomics and Theranostics
Editor-in-Chief: Siest, Gérard
Editorial Board Member: Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Henney, Adriano / Hirata, Rosario D. C. / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Llerena, Adrián / Maitland-van de Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Sadee, Wolfgang / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Visvikis-Siest, Sophie / Zanger, Ulrich M.
4 Issues per year
Volume 28 (2013)
Volume 27 (2012)
Volume 26 (2011)
Volume 25 (2010)
Volume 22 (2007)
Volume 21 (2006)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2001)
Volume 16 (2000)
Volume 17 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1995)
Volume 11 (1994)
Volume 10 (1992)
Volume 9 (1991)
Volume 8 (1990)
Volume 5 (1987)
Volume 4 (1982)
Most Downloaded Articles
- 6th Santorini Conference Biologie Prospective 2012
- Public Health Genomics and Personalized Healthcare: a pipeline from cell to society by Brand, Angela
- The aryl hydrocarbon receptor system by Barouki, Robert/ Aggerbeck, Martine/ Aggerbeck, Lawrence and Coumoul, Xavier
- European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies: the 2012 Declaration of Rome by Brand, Angela and Lal, Jonathan A.
- Herb-drug interactions with Danshen ( by Zhou, Xuelin/ Chan, Kelvin and Yeung, John H.K.
Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds
1Department of Applied Chemistry, BBA University, Lucknow, Uttar Pradesh, India
2A.R.S.D. College, University of Delhi, New Delhi, India
3Department of Chemistry, MNNIT Allahabad, Uttar Pradesh, India
4ACBR, University of Delhi, New Delhi, India
Citation Information: Drug Metabolism and Drug Interactions. Volume 28, Issue 1, Pages 31–47, ISSN (Online) 2191-0162, ISSN (Print) 0792-5077, DOI: 10.1515/dmdi-2012-0036, February 2013
- Published Online:
Background: Type 2 diabetes is the most common form of diabetes, accounting for over 90% of cases. Current treatment approaches for type 2 diabetes include diet, exercise, and a variety of pharmacologic agents, including insulin, biguanides, sulfonylureas, and thiazolidinediones.
Methods: In the present scenario, researchers focused themselves on thiazolidine ring-based compounds to cure type 2 diabetes mellitus. Among the peroxisome proliferator activated receptor (PPAR) family, PPAR-γ is the most effective in curing glucose homeostasis.
Results and conclusions: Thiazolidine ring-based compounds act as PPAR-γ agonists, and herein, we have successfully developed nine derivatives of thiazolidine ring-based compounds that are found to be biologically potent using two-dimensional quantitative structure-activity relationship model.